Spyre Therapeutics, Inc.
SYRE
$16.67
$0.784.91%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 23.01% | 19.17% | 93.69% | -- | -- |
| Gross Profit | -23.01% | -19.17% | -93.69% | -- | -4,843.60% |
| SG&A Expenses | 2.42% | -7.02% | -23.46% | 24.04% | 75.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.64% | 12.13% | 28.27% | 66.62% | 138.68% |
| Operating Income | -17.64% | -12.13% | -28.27% | -66.62% | -147.91% |
| Income Before Tax | 5.46% | -2.20% | 10.90% | -72.08% | 82.11% |
| Income Tax Expenses | -- | -146.88% | -- | 500.00% | -- |
| Earnings from Continuing Operations | 5.46% | -2.09% | 10.90% | -72.11% | 82.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.46% | -2.09% | 10.90% | -72.11% | 82.11% |
| EBIT | -17.64% | -12.13% | -28.27% | -66.62% | -147.91% |
| EBITDA | -- | -- | -27.88% | -66.06% | -151.95% |
| EPS Basic | 16.90% | 17.20% | -99.66% | 85.48% | 98.96% |
| Normalized Basic EPS | 9.65% | 38.08% | 75.55% | 89.42% | 95.67% |
| EPS Diluted | 16.90% | 17.20% | -99.66% | 85.48% | 98.96% |
| Normalized Diluted EPS | 9.65% | 38.08% | 75.55% | 89.42% | 95.67% |
| Average Basic Shares Outstanding | 33.14% | 65.05% | 254.05% | 1,085.18% | 1,085.48% |
| Average Diluted Shares Outstanding | 33.14% | 65.05% | 254.05% | 1,085.18% | 1,085.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |